IDEAYA Biosciences (IDYA)

Executive Summary

IDEAYA Biosciences is a clinical-stage precision oncology company leveraging synthetic lethality to develop targeted therapies for genetically defined patient populations. The company's lead asset, darovasertib, is in a Phase 3 trial for uveal melanoma, with enrollment ongoing and potential for an interim analysis in late 2026. IDEAYA is also advancing multiple Phase 1/2 programs, including IDE196 combinations in metastatic uveal melanoma and IDE397 for solid tumors, which could yield proof-of-concept data. The recent initiation of a Phase 3 trial for darovasertib marks a critical milestone, while partnerships with GSK and others validate the platform. Despite early-stage risk, IDEAYA's focus on synthetic lethality and biomarker-driven development positions it for multiple value-inflection points in the near term.

Upcoming Catalysts (preview)

• Q4 2026Darovasertib Phase 3 Interim Analysis50% success
• Q2 2026IDE196 Combination Phase 1/2 Data Update60% success
• Q3 2026GSK4418959 Combo Phase 1/2 Data Readout40% success